APCR
7 days
This assay measures the effect of adding aPC on the activated partial thromboplastin time (aPTT) of the patient sample.
Accredited Laboratory Partner
Contact Technical Support
Detects resistance to activated protein C, often due to Factor V Leiden mutation. Used to assess risk of venous thromboembolism.
Plasma
1 mL
Blue top (sodium citrate) tube
Do not draw from an arm with a heparin lock or heparinized catheter. Ideally, the patient should not be on anticoagulant therapy. Avoid warfarin (Coumadin®) therapy for two weeks prior to the test and heparin (direct Xa and thrombin inhibitor therapies) for about three days prior to testing.
Strictly frozen, requires own sample container. Citrated Plasma samples should be collected by double centrifugation
| Temperature | Period |
|---|---|
| Frozen | 28 days |
| Freeze/thaw cycles | Stable x3 |
APCR
7 days
This assay measures the effect of adding aPC on the activated partial thromboplastin time (aPTT) of the patient sample.
Accredited Laboratory Partner
Contact Technical Support
Detects resistance to activated protein C, often due to Factor V Leiden mutation. Used to assess risk of venous thromboembolism.
Plasma
1 mL
Blue top (sodium citrate) tube
Do not draw from an arm with a heparin lock or heparinized catheter. Ideally, the patient should not be on anticoagulant therapy. Avoid warfarin (Coumadin®) therapy for two weeks prior to the test and heparin (direct Xa and thrombin inhibitor therapies) for about three days prior to testing.
Strictly frozen, requires own sample container. Citrated Plasma samples should be collected by double centrifugation
| Temperature | Period |
|---|---|
| Frozen | 28 days |
| Freeze/thaw cycles | Stable x3 |